Background Human Papillomavirus (HPV) is the most common sexually transmitted infection in the United States, with a prevalence of roughly 79 million Americans currently infected and approximately 14 million new infections each year. Although there is a highly effective vaccination on the market for HPV, the prevalence of the infection and its associated morbidities and cancers are extremely high. The unique political landscape in each individual state can directly affect the uptake rates of the HPV vaccine. All 50 states and Washington D.C. were studied to understand if certain combinations of policies correlate to higher uptake rates. Research Objective There are five state policies that were considered when analyzing the uptake rates of ...
Background. HPV is the underlying cause of cervical cancer, a malignant tumor of the female genital ...
Human Papillomavirus is one of the most common sexually transmitted infections (STI) worldwide and i...
Objective. In June 2006, the first vaccine for human papillomavirus (HPV) was approved by the FDA an...
Purpose: To examine the policies state governments pursued and enacted across the United States in t...
A cross-sectional analysis of human papillomavirus (HPV) vaccine statutes and regulations from state...
It is estimated that 75% of the sexually active population has had an HPV infection. In June 2006 th...
Legislation introduced by two members of the District of Columbia Council on January 9, 2007 would r...
Abstract Background The human papillomavirus (HPV) vaccine is an underutilized cancer control practi...
Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the US. Infect...
We tested the hypothesis that states with higher rates of cancers associated with human papillomavir...
Abstract This article explores the political dimensions of policy formation for the human papillomav...
Background: Several studies have reported differential vaccine uptake outcomes that are associated w...
Objective: The objective was to investigate how state level strategies in South Carolina could maxim...
Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States an...
State legislatures across the nation have been considering whether to make HPV vaccination a prereq...
Background. HPV is the underlying cause of cervical cancer, a malignant tumor of the female genital ...
Human Papillomavirus is one of the most common sexually transmitted infections (STI) worldwide and i...
Objective. In June 2006, the first vaccine for human papillomavirus (HPV) was approved by the FDA an...
Purpose: To examine the policies state governments pursued and enacted across the United States in t...
A cross-sectional analysis of human papillomavirus (HPV) vaccine statutes and regulations from state...
It is estimated that 75% of the sexually active population has had an HPV infection. In June 2006 th...
Legislation introduced by two members of the District of Columbia Council on January 9, 2007 would r...
Abstract Background The human papillomavirus (HPV) vaccine is an underutilized cancer control practi...
Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the US. Infect...
We tested the hypothesis that states with higher rates of cancers associated with human papillomavir...
Abstract This article explores the political dimensions of policy formation for the human papillomav...
Background: Several studies have reported differential vaccine uptake outcomes that are associated w...
Objective: The objective was to investigate how state level strategies in South Carolina could maxim...
Human papillomavirus (HPV) is the most common sexually transmitted infection in the United States an...
State legislatures across the nation have been considering whether to make HPV vaccination a prereq...
Background. HPV is the underlying cause of cervical cancer, a malignant tumor of the female genital ...
Human Papillomavirus is one of the most common sexually transmitted infections (STI) worldwide and i...
Objective. In June 2006, the first vaccine for human papillomavirus (HPV) was approved by the FDA an...